3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Molecular Targeting Technologies, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors 177Lu-DOTA-EB-TATE, Amino Acid Solution - Neuroendocrine Tumors | Phase 1 | Completed | Molecular Targeting Technologies, Inc. | 6 | 2022-06-18 | 2026-10-26 |
| Biodistribution and Dosimetry of 99mTc-Duramycin 99mTc-Duramycin - Healthy Volunteers | Phase 1 | Completed | University Hospital, Antwerp | 6 | 2021-06-17 | 2022-01-27 |
| Study of 99mTc-glucarate to Detect Acute Coronary Syndrome in Chest Pain Patients. 99mTc-glucarate solution - Acute Coronary Syndrome | Phase 2 | Completed | Molecular Targeting Technologies, Inc. | 66 | 2008-10-01 | 2013-10-24 |
Acute Coronary Syndrome (1) · Neuroendocrine Tumors (1)
(177)Lu-DOTA-EB-TATE (1) · Cell Death (1) · amino-acid, glucose, and electrolyte solution (1) · technetium 99m HYNIC-duramycin (1)
United States (2) · Belgium (1)
Albert J. Sinusas, MD (1) · Ami E Iskandrian, MD (1) · Diwakar Jain, MD (1) · Lisa Bodei, MD, PhD (1) · Prem Soman, MD, Ph.D. (1) · Robert S Jones, MD (1) · Sigrid Stroobants, prof (1)
R44HL062770 (1)